Johnson Johnson DEVICES COMPANIES

Bruce R. Rosengard, MD, FRCS

Chief Medical Science and Technology Officer Johnson & Johnson Medical Devices Companies

Bruce R. Rosengard is the Chief Medical Science and Technology Officer for Johnson & Johnson Medical Devices Companies. In this role, he is responsible for creating and delivering on a future oriented, strategic, and relevant medical innovation strategy. Bruce and his team will identify emerging surgical trends and novel technology platforms with the goal of bringing innovative device solutions in the surgical and interventional spaces into the Medical Devices portfolio.

A cardiothoracic surgeon and NIH-funded scientist, Dr. Rosengard, previously served as Vice President, New Business Ventures for The Medicines Company, where he played a pivotal role in several major acquisitions that have expanded the Medicines Company's Surgical and Perioperative Care franchise. Before joining The Medicines Company, Bruce was the Surgical Director of Cardiac Transplantation at Massachusetts General Hospital and on the faculty of Harvard Medical School. In addition to leading the clinical program, he ran an NIH-funded laboratory in transplantation immunology. Prior to this, Dr. Rosengard was the inaugural British Heart Foundation Professor and Chairman at the University of Cambridge, where he pioneered "beating heart" transplantation. Bruce started his career at The University of Pennsylvania, where he performed the first combined heart-lung transplant at the institution, described a novel cellular mechanism responsible for triggering of transplant rejection, and patented a stem cell-based therapy to treat congestive heart failure.

Bruce was graduated summa cum laude from Tufts University with a double major in Biology and Chemistry. He obtained his MD degree from John Hopkins, where he also completed his postgraduate training in general surgery, cardiothoracic surgery, and surgical critical care. During his training, he also completed a two-year postgraduate fellowship in transplantation immunology at the National Cancer Institute. Bruce has authored more than 80 peer-reviewed publications, has given more than 40 invited talks at national or international meetings, and has served on the Boards of several professional societies.